Steven L. Goldberg, MD to Present Update on the CARILLON® Mitral Contour System™ During the Transcatheter Cardiovascular Therapeutics Conference
(KIRKLAND, WA), November 7, 2011—Cardiac Dimensions®, Inc. today announced
that an update to its landmark TITAN clinical trial will be given as part of
the 23rd annual Transcathether Cardiovascular Therapeutics (TCT) Conference
being held at the Moscone Center in San Francisco. Steven L. Goldberg, M.D.,
the Company’s Chief Clinical Officer will deliver a presentation entitled,
Cardiac Dimensions CARILLON XE2: Foundational Results and Design Iteration
Toward a Pivotal Clinical Trial. His presentation will be given on
Wednesday, November 9 at 2:40 PM PST in Room 135 as part of an in-depth
session focused on next generation transcatheter mitral valve therapies.
TITAN was a prospective, non-randomized, double-arm study evaluating
CARILLON in functional mitral regurgitation (FMR) patients. Results from the
trial will be highlighted as part of the talk, including presentation of
two-year clinical efficacy data. The data demonstrate early and sustained
improvements in functional capacity, as well as significant improvements in
mitral regurgitation and left ventricular dilation.
“CARILLON offers
a novel approach to the treatment of FMR and with the availability of
two-year data indicating clinical efficacy, the potential applications of
this therapy will be better understood,” stated Dr. Goldberg. “As a
practicing cardiologist, I see first hand how challenging it can be to treat
these patients given their limited treatment options. It is encouraging to
see the initial positive experiences with CARILLON become validated with
longer-term data. The clinical data suggest that CARILLON is a treatment
modality with compelling prospects for counterbalancing the deleterious
effects of FMR.”
About CARILLON® Mitral Contour System™
Cardiac Dimensions’ CARILLON Mitral Contour System combines a
proprietary, implantable device with a percutaneous catheter delivery
system. The implantable device consists of a proximal anchor and a distal
anchor connected by a shaping ribbon. Utilizing the heart’s natural
structures, the device is intended to reduce mitral annulus dilatation upon
deployment, thereby significantly reducing functional mitral regurgitation
(FMR). Rapidly delivered via the venous vasculature, CARILLON has the
potential to treat most heart failure patients in a minimally invasive
fashion. Early clinical data suggest that usage is associated with
significant reduction in FMR, and significant improvement in functional
capacity and quality of life.
About Functional Mitral
Regurgitation
More than 20 million people worldwide have heart
failure, most of whom also suffer from functional mitral regurgitation
(FMR). FMR typically results from the dilation of the left ventricle, which
is the main pumping chamber in the heart. As the left ventricle increases in
size, the mitral valve also expands. This dimensional increase leads to
mitral regurgitation, which significantly reduces the amount of blood flow
out of the left ventricle and on to the body and its organs. FMR has been
associated with high rates of mortality, reduced functional capacity, poor
quality of life and an increase in patient hospitalizations. Current
mainstream therapies to address FMR are limited. A majority of patients
become refractory to medical therapy over time and traditional surgical
intervention is associated with high rates of operative morbidity and
mortality.
About Cardiac Dimensions®, Inc.
Cardiac Dimensions is a leader in the development of innovative, minimally
invasive treatment modalities to address heart failure and related
cardiovascular conditions. The company’s initial technology platform, the
CARILLON® Mitral Contour System™ has been designed to address functional
mitral regurgitation, utilizing a novel percutaneous approach. Cardiac
Dimensions is based in Kirkland, Washington. For more information, visit the
company’s web site: http://www.cardiacdimensions.com.
Cardiac
Dimensions and CARILLON are registered trademarks of Cardiac Dimensions,
Inc., and Mitral Contour System is a trademark of Cardiac Dimensions, Inc.
For further information contact:
Cardiac
Dimensions, Inc.
Omari Bouknight
(425) 605-5960
Allen & Caron,
Inc.
Len Hall
(949) 474-4300